![Tom Maniatis](/biofrontiers/sites/default/files/styles/small/public/people/tommaniatis.jpg?itok=izQGcOCY)
Dr. Maniatis is a molecular biologist who studies the mechanism of gene regulation. He is also cofounder and Scientific Director of the New York Genome Center, a multi-institutional hub of genomic research serving the medical and academic institutions in New York. Dr. Maniatis leads collaborative research activities at the Center, which are focused on the development and application of genomic technology to the understanding and treatment of cancer and neurological diseases. Dr. Maniatis is known for pioneering the development of gene cloning technology and its application to basic research and biotechnology. He also coauthored the definitive laboratory manual on Molecular Cloning in the 1980’s, which profoundly impacted the international dissemination of gene cloning technology. His research has led to fundamental advances in understanding the mechanisms of gene regulation and RNA splicing, the biochemistry of innate immunity signaling pathways, the function of single cell diversity in the nervous system, and neurodegenerative disease mechanisms. Dr. Maniatis’ research has been recognized by many awards, including the Eli Lilly Award in Microbiology and Immunology, the Richard Lounsbery Award from the U.S. and French National Academies of Sciences, and the 2012 Lasker-Koshland Special Achievement Award in Medical Science.ÌýHe is a member of the U.S. National Academy of Science, the National Academy of Medicine, and a Fellow of the American Academy of Arts and Sciences. Dr. Maniatis co-founded the biotechnology companies Genetics Institute, ProScript, Acceleron, and Kallyope, which have developed several FDA approved drugs.